Login / Signup

[Immunosuppressive therapy as a risk factor for new-onset diabetes after transplantation].

S S AllazovaM S NovikovaO N KotenkoE M Shilov
Published in: Terapevticheskii arkhiv (2020)
13% of recipients developed de novo kidney diabetes after allograft. Age at the time of allotransplantation, gender, as well as the use of tacrolimus in combination with i-mTOR are the most significant risk factors for the development of NODAT.
Keyphrases
  • type diabetes
  • cardiovascular disease
  • glycemic control
  • kidney transplantation
  • cell proliferation
  • mental health
  • cell therapy
  • stem cells
  • adipose tissue
  • metabolic syndrome
  • insulin resistance
  • chemotherapy induced